Global Contrarian

Looking for unique opportunities around the world- often in EM, small/micro-cap or orphaned places

    • Global ContrarianGlobal Contrarian
      ·16:23
      13Comment
      Report
    • Global ContrarianGlobal Contrarian
      ·16:23
      24Comment
      Report
    • Global ContrarianGlobal Contrarian
      ·16:22

      Precious Metals Trading Call - weekend spike?

      Precious metals have performed very strongly and we may be approaching a good profit take opportunity, with a plurality of potential catalysts this weekend providing for a short term trade over the weekend: 1) USA Government shutdown. 2) Potential USA military actions vs Iran (or elsewhere), assuming Trump's recent preferred timing over weekends for such events. 3) Minneapolis escalation - it has been brutally cold and snowy weather the last few days and is due to moderate, alongside if being a weekend. We could see increased people on the streets. It's not improbable several or all of these occur simultaneously, leading to a classic buy the rumour, sell the fact trade on gold and silver, onmonday, in particular call options on both.$SPDR Gold ETF
      91Comment
      Report
      Precious Metals Trading Call - weekend spike?
    • Global ContrarianGlobal Contrarian
      ·01-27 12:47

      SK Telecom Update - AI buzz continuing

      $SK Telecom(SKM)$   More buzz around SK Telecom becoming a local AI champion. The trade is working and should continue short term. Also, recently announced new tarrifs on Korea could help this trade, as investors look for secular growth tech stories, domestically focused rather than more cyclical export orientated tech names.
      22Comment
      Report
      SK Telecom Update - AI buzz continuing
    • Global ContrarianGlobal Contrarian
      ·01-23
      $BUSYMING(01768)$ I have subscribed for this one!
      254Comment
      Report
    • Global ContrarianGlobal Contrarian
      ·01-23
      $IBRX 20270115 15.0 CALL$ See my article for more info on the investment case for ImmunituBio
      327Comment
      Report
    • Global ContrarianGlobal Contrarian
      ·01-23
      $IBRX 20270115 10.0 CALL$ See my article for more info on the investment case for ImmunituBio
      214Comment
      Report
    • Global ContrarianGlobal Contrarian
      ·01-23
      $ImmunityBio, Inc.(IBRX)$ See my article for more details on the exciting investment case for ImmunityBio, sitting at the confluence of AI and cancer therapies development
      396Comment
      Report
    • Global ContrarianGlobal Contrarian
      ·01-23

      ImmunityBio Investment Case- AI & Cancer treatment

      ImmunityBio is founded by Dr Patrick Soon-Shiong, who grew up as an ethnically Chinese person under apartheid South Africa- a real 'outsider' mentality Founder., whose success cannot be attributed to luck of birth. The company is at an inflection point: 1) Using AI to advance new therapies for cancer treatments (enormous total addressable market), whilst also drastically reducing costs. And removing/reducing surgical procedures. 2) Shares were out of favour due to lofty IPO expectations and lobby efforts to protect the enormous profits others are making from the USA healthcare sy
      1.65K2
      Report
      ImmunityBio Investment Case- AI & Cancer treatment
    • Global ContrarianGlobal Contrarian
      ·01-22
      $Soluna Holdings, Inc.(SLNHP)$ $Soluna Holdings, Inc.(SLNH)$   To follow on from my article on Soluna Holdings, two other points are relevant: 1. The company is controlled by a private equity firm, which makes a change of control almost inevitable in the end - this underpins the special situation nature of Soluna preferreds, who are entitled to receive $25 + accrueed interest (>$5 currently). 2. Further more, whilst the preferred dividend is not being paid currently, it is still accuring at $1.75/year, so one is earning >15% whilst we wait. 3. Insiders received 2m preferred shares in summer 2024 as part of incentive plans - this was after the dividend had been halted. Why would you issue a eff
      299Comment
      Report
       
       
       
       

      Most Discussed